Login / Signup

Point-Counterpoint: Should Clinical Microbiology Laboratories Report Vancomycin MICs?

Sara L RevolinskiChristopher D Doern
Published in: Journal of clinical microbiology (2021)
INTRODUCTIONWith numerous reported challenges to reporting MICs for vancomycin, clinical laboratories are attempting to identify accurate methods for MIC testing. However, the issues of poor reproducibility, accuracy, and clinical utility remain a challenge. In this Point-Counterpoint, Dr. Sara Revolinski discusses the pros of reporting MICs for vancomycin, while Dr. Christopher Doern argues for the use of caution.
Keyphrases
  • methicillin resistant staphylococcus aureus
  • adverse drug
  • editorial comment
  • emergency department
  • electronic health record
  • infectious diseases